



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

## MicroSource DSI

[View the current MicroSource DSI Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7068-MicroSource+DSI.html)

(<http://www.bioportfolio.com/biocorporate/7068-MicroSource+DSI.html>)

### Contact Details:

21 George Washington Plaza  
Gayordsville  
CT  
06755  
United States of America

Tel: 860 350 8078  
Fax: 860 354 5300  
Email:

### Press Releases on MicroSource DSI:

<a href="#">Survivors of Heart Events: What Does it Take to Get Back to Living?</a>	22nd September, 2009	Eli Lilly and Company	<i>-- 93% of patients who feel they had been given a second chance in life viewed it as an opportunity to do things better. -- Only 17% strongly agreed that they were worried about</i>
<a href="#">Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes</a>	15th May, 2009	Daiichi Sankyo, Inc.	<i>- Welchol Added to Metformin Significantly Reduced A1C and LDL-C in Patients with Type 2 Diabetes - Open-Label Extension Study Demonstrated the Safety and Durability of Welchol for up to 78 Weeks of</i>
<a href="#">Daiichi Sankyo, Inc. Celebrates the Growth of Its U.S. Headquarters</a>	13th May, 2009	Daiichi Sankyo, Inc.	<i>Caren Franzini, CEO of New Jersey Economic Development Authority, highlights New Jersey's talented workforce and strategic location as factors for economic growth and prosperity PARSIPPANY, N.J.</i>

[Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia](#)

11th November, 2008

Daiichi Sankyo, Inc. (DSI)

*First Presentation of Pivotal Study Data in Pediatric Patients Presented at the American Heart Association's Annual Scientific Sessions 2008 PARSIPPANY, N.J., Nov. 11 /PRNewswire-FirstCall/ --*

[Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment](#)

9th September, 2008

Kidney Care Partners

*National Dialysis Providers, Patient Advocates Work with Local Kidney Community to Prepare for Storm's Impact CORPUS CHRISTI, Texas, Sept. 9 /PRNewswire-USNewswire/ -- With the highest per*

## BioNews Results for MicroSource DSI



- [FDA approves sNDA for pediatric autism drug ABILIFY](#)  
*News-Medical.Net: Nov 21 2009 4:57AM Matching: dsi*
- [FDA approves CSL Biotherapies' seasonal flu vaccine, Afluria for children](#)  
*News-Medical.Net: Nov 12 2009 10:45AM Matching: dsi*
- [The Role of FDAs Center for Drug Evaluation and Research \(CDER\) in Disqualifying Researchers from Clinical Trials for New Medications](#)  
*FDA: Nov 3 2009 2:00AM Matching: dsi*
- [FDA approves an expanded indication for BYETTA injection](#)  
*News-Medical.Net: Oct 31 2009 4:47AM Matching: dsi*
- [EB Sport announces the availability two branded fitness kits for men and women](#)  
*News-Medical.Net: Oct 29 2009 4:23PM Matching: dsi*
- [Content Data Solutions Brings CCGMPs Library of Medical Publications Online](#)  
*Yahoo! Canada: Oct 28 2009 11:03PM Matching: dsi*
- [BioSoteria Drug Safety Newsletter Reaches Milestone](#)  
*Individual.com: Oct 22 2009 8:21AM Matching: dsi*
- [Determinants of post-exercise heart rate recovery in patients with the obstructive sleep apnea syndrome](#)  
*CHEST: Oct 19 2009 10:14PM Matching: dsi*
- [Welchol \(colesevelam HCl\) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygo](#)  
*Pharmacy Choice: Oct 19 2009 10:22AM Matching: dsi*
- [Welchol \(colesevelam HCl\) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygo](#)  
*Pharma Live: Oct 7 2009 4:05PM Matching: dsi*
- [Daiichi Sankyo extends pact with Syngy for sales performance management solutions](#)  
*PharmaBiz: Sep 1 2009 6:40AM Matching: dsi*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

